Mark Eliason is a Dermatology physician affiliated with University of Utah. OpenAlex indexes 21 publications with 938 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
University Hospital
1900 East 50 North Medical Dr.
Salt Lake City, UT 841320001
Telephone
801-581-6465Provider last certified this registry record 2 Dec 2021.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novartis Pharmaceuticals CorporationProgram year20258 payments
- Regeneron Healthcare Solutions, Inc.Program year20251 payment
- Lilly USA, LLCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
19.3%Azole Antifungal7.4%Ketoconazole100%Part D≥22 patientsLincosamide Antibacterial4.6%Clindamycin Phosphate100%Part D≥19 patients+ 3 more classes in this area
Respiratory
18.6%RNA Synthetase Inhibitor Antibacterial15.1%Mupirocin100%Part D≥82 patientsCorticosteroid3.5%Mometasone Furoate100%Part D≥15 patientsDermatology
18.2%Corticosteroid15.7%Triamcinolone Acetonide100%Part D≥71 patientsInterleukin-4 Receptor alpha Antagonist2.5%Dupixent Syringe100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 247 The administrative burden and costs of prior authorizations in dermatology
Journal of Investigative Dermatology
2019 - Process of Post-operative Telephone Follow-up Implementation for Mohs Micrographic Surgery: A Pilot Study.
PubMed
2018 - The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review
Journal of the American Academy of Dermatology
2016
Similar KOLs
Other experts from the same institution or the same specialty.
Frederick Welt, MD
University of Utah
Jennifer Majersik, MD
University of Utah
Richard Gurgel, MD
University of Utah
Fuad Shihab, MD
University of Utah
Robert Modlin, MD
University of California, Los Angeles
Heidi Kong, MD
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Jon Hanifin, MD
Oregon Health & Science University (OHSU)
Victoria Werth, MD
Perelman School of Medicine at the University of Pennsylvania
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”